Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Novabay Pharmaceuticals (NBY)

0.6404   -0.015 (-2.24%) 07-29 04:15
Open: 0.6495 Pre. Close: 0.6551
High: 0.6849 Low: 0.6305
Volume: 2,584,945 Market Cap: 27M
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. The company is headquartered in Emeryville, California and currently employs 70 full-time employees. The firm focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. The company develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The firm's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.681 - 0.684 0.684 - 0.687
Low: 0.621 - 0.625 0.625 - 0.629
Close: 0.633 - 0.639 0.639 - 0.645

Technical analysis

as of: 2021-07-28 4:45:57 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.81     One year: 0.90
Support: Support1: 0.56    Support2: 0.47
Resistance: Resistance1: 0.69    Resistance2: 0.77
Pivot: 0.62
Moving Average: MA(5): 0.64     MA(20): 0.63
MA(100): 0.77     MA(250): 0.81
MACD: MACD(12,26): -0.01     Signal(9): -0.02
Stochastic oscillator: %K(14,3): 41.97     %D(3): 45.95
RSI: RSI(14): 49.11
52-week: High: 1.79  Low: 0.52  Change(%): -45.3
Average Vol(K): 3-Month: 165949  10-Days: 533247

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
NBY has closed below upper band by 32.9%. Bollinger Bands are 47.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to NBY's normal range. The bands have been in this narrow range for 46 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Wed, 28 Jul 2021
Novabay (NBY) falls 2.24% to Close at $0.64 on July 28 - Equities.com

Wed, 28 Jul 2021
NovaBay Pharmaceuticals Inc. (NBY) stock is likely to drive top-line growth - BOV News

Tue, 27 Jul 2021
NovaBay Pharmaceuticals, Inc. (NBY) Stock Gains 24.14% This Week: Is It a Good Pick? - InvestorsObserver

Tue, 27 Jul 2021
NovaBay Pharmaceuticals Inc. (AMEX: NBY) Disappoints Wall Street With -1.45% Stock Price Loss - Marketing Sentinel

Tue, 27 Jul 2021
Novabay (NBY) falls 1.45% to Close at $0.62 on July 26 - Equities.com

Fri, 23 Jul 2021
A -392.42% Or Greater Growth Is Projected For NovaBay Pharmaceuticals Inc. (AMEX: NBY) - Marketing Sentinel

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  AMEX
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 42
Shares Float (M) 33
% Held by Insiders 41.27
% Held by Institutions 6.53
Shares Short (K) 515
Shares Short P. Month (K) 546

Stock Financials

EPS -0.361
EPS Est This Year -0.470
EPS Est Next Year -0.090
Book Value (p.s.) 0.030
Profit Margin -97.79
Operating Margin -68.19
Return on Assets (ttm) -34.0
Return on Equity (ttm) -681.2
Qtrly Rev. Growth 122.7
Gross Profit (p.s.) 0.116
Sales Per Share 0.221
EBITDA (p.s.) -0.149
Qtrly Earnings Growth
Operating Cash Flow (M) -5
Levered Free Cash Flow (M) -2

Stock Valuations

PE Ratio -1.77
PEG Ratio
Price to Book value 21.35
Price to Sales 2.89
Price to Cash Flow -5.53

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.